NabGen, Inc., founded in North Carolina, is a biotech company dedicated to advancing gene therapy by overcoming the challenge of patient-derived anti-drug antibodies. Their core mission is to ensure that all patients can benefit from gene therapy treatments, regardless of pre-existing vector immunity. NabGen's primary product is a universal antibody suppressant platform designed to enable successful administration of AAV-based therapeutics and create opportunities for redosing.
Notable figures associated with NabGen include experts in biotechnology and gene therapy, though specific names are not provided. The company has attracted significant interest from investors focused on innovative healthcare solutions. NabGen's key achievements include developing a platform with broad applications in gene therapy, potentially transforming treatment protocols and improving patient outcomes. Their work has a substantial impact on the field by addressing a critical barrier in gene therapy delivery.
